Saturday, January 11, 2020, Houston, Texas, 8:00 AM – 4:00 PM

Year in Review: A Multitumor Regional Symposium Focused on the Application of Emerging Research Information to the Care of Patients with Common Cancers

Saturday, January 11, 2020

Program Time
8:00 AM – 4:00 PM
Breakfast and lunch buffet to be provided

The Westin Galleria Houston
5060 W Alabama Street
Houston, TX 77056
Hotel Phone: (713) 960-8100

Meeting Room
Woodway II and III (Fourth Level)

Hotel Accommodations
A special rate of $119 (Traditional King Room) has been arranged for the meeting. Please see the Location tab for additional details.

There is no registration fee for this event. Preregistration is advised as seating is limited.

Breast Cancer

Erika Hamilton, MD
Director, Breast and Gynecologic
Research Program
Sarah Cannon Research Institute
Nashville, Tennessee

Sara Hurvitz, MD
Associate Professor of Medicine
David Geffen School of Medicine at UCLA
Director, Breast Cancer Clinical Research Program
Co-Director, Santa Monica-UCLA Outpatient
Oncology Practice
Santa Monica, California

Acute Leukemias

Harry P Erba, MD, PhD
Professor, Department of Medicine
Director of the Leukemia Program
Division of Hematologic Malignancies
and Cellular Therapy
Duke Cancer Institute
Duke University School of Medicine
Durham, North Carolina

Mark Levis, MD, PhD
Director, Adult Leukemia Program
Co-Division Director, Hematologic Malignancies
Professor of Oncology
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins Medicine
Baltimore, Maryland

Lymphomas and Chronic Lymphocytic Leukemia

Bruce D Cheson, MD
Lymphoma Consultant
North Bethesda, Maryland

Loretta Nastoupil, MD
Associate Professor
Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Sonali M Smith, MD
Elwood V Jensen Professor of Medicine
Interim Chief, Section of Hematology/Oncology
Director, Lymphoma Program
The University of Chicago
Chicago, Illinois

Gastrointestinal Cancers

Tanios Bekaii-Saab, MD
Professor, Mayo Clinic College of Medicine
and Science
Program Leader, Gastrointestinal Cancer
Mayo Clinic Cancer Center
Vice-Chair and Section Lead
Division of Medical Oncology
Medical Director, Cancer Clinical Research Office
Senior Associate Consultant
Mayo Clinic
Phoenix, Arizona

Johanna Bendell, MD
Chief Development Officer
Director, Drug Development Unit Nashville
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee

Philip A Philip, MD, PhD, FRCP
Kathryn Cramer Endowed Chair in Cancer Research
Professor of Oncology and Pharmacology
Leader, GI and Neuroendocrine Oncology
Vice President of Medical Affairs
Karmanos Cancer Institute
Wayne State University
Detroit, Michigan

Genitourinary Cancers

Charles G Drake, MD, PhD
Professor of Medicine
Director, Genitourinary Oncology
Co-Director, Cancer Immunotherapy
Columbia University Medical Center
New York, New York

William K Oh, MD
Chief, Division of Hematology and
Medical Oncology
Professor of Medicine and Urology
Ezra M Greenspan, MD Professor in Clinical
Cancer Therapeutics
Icahn School of Medicine at Mount Sinai
Associate Director of Clinical Research
The Tisch Cancer Institute
Mount Sinai Health System
New York, New York

Gynecologic Cancers

Robert L Coleman, MD
Professor and Executive Director
Cancer Network Research
Ann Rife Cox Chair in Gynecology
Department of Gynecologic Oncology and
Reproductive Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Kathleen Moore, MD
The Virginia Kerley Cade Endowed Chair in
Cancer Development
Associate Director, Clinical Research
Director, Oklahoma TSET Phase I Program
Stephenson Cancer Center
Associate Professor
Section of Gynecologic Oncology
Director, Gynecologic Oncology Fellowship
Department of Obstetrics and Gynecology
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma

Lung Cancer

Stephen V Liu, MD, PhD
Associate Professor of Medicine
Georgetown University Hospital
Washington, DC

Gregory J Riely, MD, PhD
Associate Attending
Memorial Sloan Kettering Cancer Center
New York, New York

Neil Love, MD
Research To Practice
Miami, Florida


Each module will include a moderated slide presentation reviewing key publications, presentations and ongoing trials in addition to a clinical decision-making track facilitated through the use of networked iPad technology. The event will take place from 8:00 AM to 4:00 PM (breakfast and lunch buffets to be provided).

Lung Cancer

  • Optimal long-term treatment for patients with non-small cell lung cancer (NSCLC) and EGFR tumor mutations, including those with CNS metastases; documentation of an overall survival benefit with osimertinib as first-line therapy
  • Clinical and biologic factors influencing the selection of first- and later-line therapy for advanced NSCLC with an ALK rearrangement
  • Current and emerging treatment considerations for patients with NSCLC with ROS1 rearrangement
  • Mechanism of action of, available data with and ongoing evaluation of novel agents (eg, LOXO-292, BLU-667) in patients with RET fusion-driven NSCLC
  • Identification and off-protocol management of NSCLC with NTRK gene fusions
  • Early clinical trial results with and ongoing evaluation of novel agents targeting MET exon 14 mutations (eg, capmatinib, tepotinib)
  • Available data with and recent FDA approval of carboplatin/etoposide/atezolizumab for newly diagnosed extensive-stage small cell lung cancer (SCLC); appropriate integration into current SCLC management
  • Emerging results from the Phase III CASPIAN trial documenting the benefit of durvalumab in combination with etoposide and platinum-based chemotherapy versus chemotherapy alone as first-line therapy for extensive-stage SCLC
  • Efficacy and safety data with the use of anti-PD-1/PD-L1 antibodies alone or in combination with anti-CTLA-4 antibodies for patients with progressive metastatic SCLC
  • Patient selection for and practical implementation of sequential durvalumab in the management of unresectable Stage III NSCLC
  • Ongoing evaluation of other anti-PD-1/PD-L1 antibodies in the localized and locally advanced settings
  • Clinical and biologic factors affecting the selection of anti-PD-1/PD-L1 monotherapy versus combined chemotherapy/immune checkpoint inhibition
  • Implications of the recent FDA approval of atezolizumab/bevacizumab in combination with carboplatin/paclitaxel for chemotherapy-naïve metastatic nonsquamous NSCLC
  • Similarities and differences among Phase III trials evaluating anti-PD-1/PD-L1 antibodies in combination with platinum-based chemotherapy for patients with newly diagnosed metastatic squamous NSCLC; current role of combination chemoimmunotherapy as first-line treatment for this population
  • Emerging results from the Phase III CheckMate 227 trial documenting an overall survival advantage with nivolumab/low-dose ipilimumab versus chemotherapy as first-line treatment for patients with NSCLC and PD-L1 tumor expression ≥1%

Acute Leukemias

  • Published efficacy and safety data supporting the recent FDA approval of venetoclax in combination with azacitidine, decitabine or low-dose cytarabine for patients with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy
  • Optimal integration of venetoclax into current AML management: Dose, schedule, identification and management of toxicities, incidence and prophylaxis of tumor lysis syndrome
  • Design, entry criteria and key efficacy and safety findings from the Phase II BRIGHT 1003 trial of glasdegib in combination with low-dose cytarabine for newly diagnosed AML in older patients or those who are unable to receive intensive induction chemotherapy; recent FDA approval of glasdegib and integration into current care
  • Available research data with gilteritinib for FLT3 mutation-positive AML; recent FDA approval of gilteritinib for relapsed/refractory (R/R) disease and appropriate integration into routine practice
  • Published research database supporting FDA approvals of the IDH inhibitors enasidenib and ivosidenib for AML
  • Available efficacy and safety data with and FDA approval of CPX-351; current role in clinical practice and ongoing evaluation in other populations with AML
  • Initial management of Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL); comparison of adult and pediatric treatment regimens
  • FDA-endorsed use of blinatumomab for patients with minimal residual disease (MRD)-positive ALL in first or second complete remission or those with R/R disease
  • Current role of MRD assessment in ALL management and selection of optimal testing platform
  • Biologic rationale for the evaluation of chimeric antigen receptor (CAR) T-cell therapy in patients with ALL; FDA approval of tisagenlecleucel for pediatric and young adult patients and published clinical trial experience with CAR T-cell therapy in adult patients with ALL
  • Current management of acute promyelocytic leukemia

Lymphomas and Chronic Lymphocytic Leukemia (CLL)

  • Clinical implications of recent Phase III data sets comparing ibrutinib-based therapy to standard chemoimmunotherapy approaches for younger (ECOG-E1912) and older (Alliance A041202) patients with treatment-naïve CLL
  • Design, eligibility requirements and primary and secondary outcomes achieved in the Phase III CLL14 trial evaluating venetoclax/obinutuzumab versus chlorambucil/obinutuzumab for patients with treatment-naïve CLL and coexisting medical conditions; clinical implications of the recent FDA approval of this regimen
  • Clinical and biologic factors influencing the selection of first-line treatment regimen for patients with newly diagnosed CLL requiring active therapy
  • Available platforms for, clinical significance of and current protocol and nonresearch applications of MRD assessment in CLL
  • Key findings from the Phase III ASCEND trial comparing acalabrutinib to rituximab in combination with either idelalisib or bendamustine for patients with R/R CLL; ongoing Phase III ELEVATE-RR study of acalabrutinib versus ibrutinib for high-risk R/R disease
  • Emerging results from the Phase III ELEVATE-TN trial comparing obinutuzumab/chlorambucil, acalabrutinib/obinutuzumab and acalabrutinib for patients with previously untreated CLL
  • Long-term outcomes of the Phase III MURANO trial comparing venetoclax/rituximab to bendamustine/rituximab (BR) for R/R CLL
  • Key efficacy and safety outcomes from the Phase III DUO trial evaluating duvelisib versus ofatumumab for R/R CLL; FDA approval of duvelisib and optimal role of PI3 kinase inhibition in patients with R/R CLL
  • Ongoing randomized trials evaluating novel combination approaches for newly diagnosed CLL
  • Clinical and research implications of Phase III trials (RELEVANCE, AUGMENT) evaluating the “R-squared” regimen of lenalidomide/rituximab in newly diagnosed and R/R follicular lymphoma (FL); recent FDA approval of this approach for previously treated FL and marginal zone lymphoma
  • Role of obinutuzumab-based induction and maintenance therapy for previously untreated FL; integration of obinutuzumab into current algorithms for treatment-naïve and R/R disease
  • Patient selection for PI3 kinase inhibition in R/R FL; appropriate integration of idelalisib, copanlisib and duvelisib into current management algorithms
  • Early activity and safety data with ibrutinib alone or in combination with other systemic therapies for previously untreated mantle cell lymphoma (MCL); ongoing and planned Phase III trials (eg, TRIANGLE, SHINE, SYMPATICO)
  • Research database supporting the FDA approval of acalabrutinib in R/R MCL; patient selection for its use
  • Early activity, ongoing trials and current nonresearch role, if any, of venetoclax in R/R MCL
  • Long-term follow-up from clinical trials of approved and investigational CAR T-cell platforms in diffuse large B-cell lymphoma (DLBCL); appropriate referral for consideration of CAR T-cell therapy in general practice
  • Available efficacy and safety data leading to the FDA approval of polatuzumab vedotin in combination with BR for patients with R/R DLBCL; optimal incorporation into current management algorithms
  • Role of brentuximab vedotin (BV) in combination with doxorubicin/vinblastine/dacarbazine as first-line therapy for advanced classical Hodgkin lymphoma (HL); experience with North American patients in the ECHELON-1 trial and implications, if any, for the adoption of BV
  • Ongoing evaluation of immune checkpoint inhibitors alone or in combination with other systemic approaches (eg, chemotherapy, BV) for newly diagnosed or R/R HL
  • Recent FDA approval of BV in combination with chemotherapy for previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas

Gynecologic Cancers

  • Key outcomes from the Phase III SOLO-1 trial evaluating maintenance olaparib after first-line platinum-based chemotherapy for patients with advanced ovarian cancer (OC) and a BRCA mutation
  • Emerging results and clinical implications of the Phase III PRIMA study evaluating maintenance niraparib after first-line platinum-based chemotherapy for patients with advanced OC regardless of biomarker status
  • Design, eligibility criteria and emerging efficacy and safety data from the Phase III PAOLA-1 trial comparing olaparib in combination with bevacizumab to bevacizumab alone as maintenance therapy for patients with advanced OC who responded to first-line treatment with platinum-based chemotherapy and bevacizumab
  • Findings from the Phase III SOLO-3 trial comparing olaparib monotherapy to chemotherapy for platinum-sensitive relapsed OC with a germline BRCA mutation
  • Results and clinical implications of the Phase II QUADRA study of niraparib for patients with relapsed OC, regardless of mutation status, who have received 3 or 4 prior chemotherapy regimens
  • Long-term follow-up from other data sets informing the safe and effective use of PARP inhibitors for platinum-sensitive and platinum-refractory advanced OC
  • Biologic rationale and eligibility criteria for ongoing trials of PARP inhibitors combined with immune checkpoint inhibitors, anti-angiogenic agents or other systemic approaches
  • Incidence of microsatellite instability (MSI) in patients with advanced gynecologic cancers; recommended testing algorithms and activity of anti-PD-1/PD-L1 antibodies in individuals with MSI-high disease
  • Available data with, FDA breakthrough therapy designation for and ongoing evaluation of pembrolizumab/lenvatinib for advanced endometrial cancer (EC)
  • Preliminary safety and efficacy associated with the use of the anti-PD-1 antibody dostarlimab in patients with advanced or recurrent EC; ongoing evaluation and future development plans
  • Efficacy and safety associated with the use of pembrolizumab in patients with advanced cervical cancer (CC) enrolled on the Phase II KEYNOTE-158 trial
  • FDA approval of pembrolizumab for PD-L1-positive recurrent or metastatic CC with disease progression on or after chemotherapy and patient selection for its use in routine practice
  • Mechanism of action of and published efficacy and safety outcomes with the use of tisotumab vedotin in R/R CC; ongoing and planned trials evaluating the role of tisotumab vedotin in R/R and previously untreated metastatic CC
  • Ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies alone and in combination with other systemic therapies for patients with advanced OC, EC and CC
  • Other promising agents or strategies under investigation for advanced gynecologic cancers

Breast Cancer (BC)

  • Key efficacy and safety results from the Phase III KATHERINE study of adjuvant T-DM1 versus trastuzumab for patients with HER2-positive primary BC and residual disease after preoperative therapy
  • Optimal integration of pertuzumab and neratinib into the management of HER2-positive early BC
  • Available research data with neratinib/capecitabine for patients with HER2-positive mBC, including those with CNS metastases
  • Structural makeup of and early efficacy and tolerability data with the use of trastuzumab deruxtecan in patients with HER2-positive mBC; emerging pivotal data from the Phase II DESTINY-Breast01 trial
  • Mechanism of action of and early activity and safety data with the selective HER2 inhibitor tucatinib; activity in patients with HER2-positive brain metastases and ongoing evaluation
  • Available Phase III data with and potential clinical role of margetuximab
  • Implications of the TAILORx intermediate-risk cohort results for adjuvant treatment for pre- and postmenopausal patients with early BC; utility of classic clinical features to complement 21-gene Recurrence Score® findings in various patient subsets
  • Research data with and current clinical role of CDK4/6 inhibitors for premenopausal, postmenopausal and elderly patients with ER-positive mBC
  • Key efficacy and safety findings of the Phase III SOLAR-1 trial leading to the FDA approval of alpelisib/fulvestrant for men and postmenopausal women with ER-positive, HER2-negative mBC with PIK3CA mutations
  • FDA approval of atezolizumab/nab paclitaxel for patients with PD-L1-positive unresectable locally advanced or metastatic triple-negative BC; integration of this approach into clinical practice
  • Emerging results from the Phase III KEYNOTE-522 trial documenting the benefit of neoadjuvant pembrolizumab with chemotherapy versus chemotherapy alone for triple-negative BC
  • Ongoing Phase III evaluation of anti-PD-1/PD-L1 antibodies alone or in combination with other systemic therapies for localized or metastatic BC
  • Therapeutic implications of Phase III data sets supporting the FDA approvals for olaparib (OlympiAD) and talazoparib (EMBRACA) for HER2-negative mBC with a BRCA germline mutation

Gastrointestinal Cancers

  • Key outcomes from and clinical implications of the randomized Phase III Unicancer GI PRODIGE 24/CCTG PA.6 trial comparing adjuvant mFOLFIRINOX to gemcitabine for resected pancreatic adenocarcinoma (PAD)
  • Key efficacy results and clinical implications of the Phase III APACT trial evaluating adjuvant nab paclitaxel/gemcitabine versus gemcitabine alone
  • Use of contemporary chemotherapy regimens (mFOLFIRINOX, nab paclitaxel/gemcitabine) with or without radiation therapy as neoadjuvant treatment for resectable or borderline-resectable PAD
  • Published research experience with, patient selection for and practical integration of nal-IRI (nanoliposomal irinotecan) for relapsed metastatic PAD; ongoing evaluation in earlier disease settings
  • Design, entry criteria and key efficacy and safety findings from the Phase III POLO trial evaluating olaparib as maintenance therapy for patients with metastatic PAD and a germline BRCA mutation after first-line chemotherapy; diagnostic and clinical implications
  • FDA approval of lenvatinib as first-line therapy for unresectable hepatocellular carcinoma (HCC) and patient selection for its use in routine practice
  • Emerging results from the Phase III CheckMate 459 trial evaluating nivolumab as first-line treatment for advanced HCC; clinical and research implications
  • Key findings from the Phase III REACH-2 study of ramucirumab for patients with progressive HCC and an alpha-fetoprotein level of ≥400 ng/mL; recent FDA approval of ramucirumab for this patient population
  • Sequence and selection of approved agents (nivolumab, regorafenib, cabozantinib, pembrolizumab, ramucirumab) for patients whose disease has progressed on first-line therapy
  • Biologic rationale for and early trial data leading to the FDA breakthrough therapy designations for atezolizumab/bevacizumab and pembrolizumab/lenvatinib as first-line therapy for advanced HCC
  • Early safety and efficacy with and ongoing evaluation of combined anti-PD-1/PD-L1 and anti-CTLA-4 antibodies in HCC (eg, nivolumab/ipilimumab, durvalumab/tremelimumab)
  • Active Phase III trials attempting to improve outcomes over standard biologic therapy for patients with newly diagnosed, advanced HCC (eg, IMbrave150, LEAP-002, COSMIC-312, HIMALAYA)
  • Available research data exploring the correlation between tumor location and long-term outcomes in metastatic colorectal cancer (mCRC); emerging data linking tumor sidedness to response to specific therapeutic interventions
  • Rational incorporation of EGFR antibodies, regorafenib and TAS-102 into current treatment algorithms for mCRC
  • Indications for MSI assessment in mCRC; patient selection for anti-PD-1 monotherapy versus combined anti-PD-1/anti-CTLA-4 antibody therapy in patients with MSI-high/mismatch repair-deficient (dMMR) tumors
  • Biologic rationale for, available data with and ongoing investigation of regorafenib in combination with nivolumab for patients with microsatellite stable mCRC
  • Published research findings from the Phase III BEACON CRC trial comparing encorafenib/cetuximab with or without binimetinib to irinotecan/cetuximab or FOLFIRI/cetuximab for patients with mCRC and BRAF V600E mutations
  • Integration of ramucirumab into current clinical algorithms for metastatic gastric/gastroesophageal junction (GEJ) cancer; ongoing evaluation of ramucirumab for other clinical presentations beyond disease progression on first-line therapy
  • Research supporting the FDA approval of pembrolizumab for recurrent locally advanced or metastatic gastric/GEJ adenocarcinoma with a PD-L1 combined positive score ≥1 after 2 or more lines of chemotherapy and, if appropriate, HER2-targeted therapy; clinical and research implications of the Phase III KEYNOTE-061 and KEYNOTE-062 trials
  • Early experience and ongoing research combining immune checkpoint inhibitors with chemotherapy, targeted therapy or other immunotherapeutic agents for patients with metastatic gastric/GEJ cancer
  • Primary and secondary endpoints achieved in the Phase III TAGS study of TAS-102 for heavily pretreated metastatic gastric cancer; FDA approval and patient selection in routine practice
  • Results from the Phase III KEYNOTE-181 trial evaluating second-line pembrolizumab versus chemotherapy for locally advanced or metastatic squamous cell carcinoma and adenocarcinoma of the esophagus; FDA approval of pembrolizumab for progressive, PD-L1-positive advanced esophageal cancer
  • Emerging efficacy and safety findings from the Phase III ATTRACTION-3 trial comparing nivolumab to chemotherapy for unresectable advanced or recurrent esophageal cancer that is refractory to or intolerant of fluoropyrimidine with platinum-based therapy

Genitourinary Cancers

  • Published findings from the Phase III PROSPER, SPARTAN and ARAMIS trials evaluating enzalutamide, apalutamide and darolutamide, respectively, for patients with nonmetastatic castration-resistant prostate cancer (CRPC); FDA approvals of these agents and optimal integration into current clinical algorithms
  • Key clinical and practical factors guiding the selection of docetaxel or abiraterone acetate and prednisone in combination with androgen deprivation therapy (ADT) for men with metastatic hormone-sensitive PC (mHSPC)
  • Design, eligibility criteria and key efficacy outcomes from the Phase III ARCHES and TITAN studies comparing enzalutamide and apalutamide, respectively, in combination with ADT to ADT alone for patients with mHSPC
  • Benefit associated with enzalutamide in combination with ADT versus other nonsteroidal antiandrogen agents (eg, bicalutamide, nilutamide, or flutamide) with ADT for patients with mHSPC in the Phase III ENZAMET trial
  • Early clinical trial data with the use of olaparib and rucaparib for patients with progressive mCRPC; FDA breakthrough therapy designations and ongoing investigation
  • Emerging results from the Phase III PROfound trial evaluating olaparib versus enzalutamide or abiraterone for mCRPC after failure of prior hormonal therapy in patients with homologous recombination repair gene mutations
  • Research database examining the utility of androgen receptor splice variant 7 expression as a predictive marker for response to secondary hormonal therapy in patients with mCRPC; commercially available platforms and current clinical role
  • Patient selection for, practical implementation of and ongoing evaluation of radium-223 dichloride
  • Supporting research database underlying the FDA approvals of pembrolizumab/axitinib, axitinib/avelumab, nivolumab/ipilimumab and cabozantinib for patients with newly diagnosed metastatic renal cell carcinoma (mRCC)
  • Clinical and biologic factors influencing the selection of first-line therapy for patients with newly diagnosed mRCC
  • Available data with and ongoing evaluation of other anti-PD-1/PD-L1 antibody/multikinase inhibitor combinations (eg, pembrolizumab/lenvatinib, nivolumab/ipilimumab/cabozantinib) as first-line therapy for advanced RCC; FDA breakthrough therapy designation for front-line pembrolizumab/lenvatinib
  • Evidence-based and guideline-endorsed approaches to the treatment of mRCC progressing on first-line therapy
  • Optimal integration of anti-PD-1/PD-L1 antibodies into the management of progressive metastatic urothelial bladder cancer (UBC)
  • Current indications for the use of anti-PD-1/PD-L1 antibodies in previously untreated metastatic UBC; significance of PD-L1 status and platinum eligibility
  • Emerging results from the Phase III IMvigor130 trial documenting the benefit of atezolizumab with platinum-based chemotherapy versus chemotherapy alone for previously untreated locally advanced or metastatic UBC
  • Rationale for and ongoing evaluation of novel regimens combining anti-PD-1/PD-L1 antibodies with anti-CTLA-4 antibodies, chemotherapy or targeted therapy
  • Available data with and ongoing Phase III trials of immune checkpoint inhibitors for patients with nonmetastatic UBC
  • Efficacy and safety data supporting the recent FDA approval of erdafitinib for patients with locally advanced or metastatic UBC with susceptible FGFR3 or FGFR2 genetic alterations who have experienced disease progression on or after platinum-based chemotherapy
  • Preliminary data from the pivotal Phase II EV-201 trial evaluating enfortumab vedotin in patients with locally advanced or metastatic UBC who previously received immune checkpoint inhibitor therapy; FDA breakthrough therapy designation and potential clinical role

Target Audience
This live activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, nurse practitioners, clinical nurse specialists and other allied cancer professionals.

Learning Objectives
At the conclusion of this activity, participants should be able to:

  • Effectively apply the results of practice-changing clinical research to the care of patients with breast, gastrointestinal, genitourinary, gynecologic, lung and select hematologic cancers.
  • Appraise the clinical relevance of recent pivotal cancer research results published in peer-reviewed journals and/or presented at major oncology conferences.
  • Recall ongoing trials in breast, gastrointestinal, genitourinary, gynecologic, lung and select hematologic cancers, and refer appropriate patients for study participation.
  • Incorporate clinical characteristics, logistical factors, tumor biomarkers and single and multigene signatures to individualize the care of patients with cancer.
  • Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
  • Refine or validate existing cancer treatment algorithms based on exposure to new data sets and the perspectives of tumor-specific clinical investigators.
  • Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider the implications for clinical practice.

Accreditation Statements
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

CME Credit Designation Statement
Research To Practice designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit Designation Statements
This educational activity for 6.75 contact hours is provided by Research To Practice.

This activity is awarded 6.75 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the ONCC and is acceptable for recertification points. To review certification qualifications please visit

ONCC review is only for designating content to be used for ILNA points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

CME Credit Form
A credit form will be given to each participant at the conclusion of the activity.

CNE Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME/CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP, ACCME or the ANCC. Any off-label use as declared by the FDA will be identified.

Educational Support
This activity is supported by educational grants from AbbVie Inc, Adaptive Biotechnologies, Amgen Inc, Array BioPharma Inc, Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boston Biomedical Inc and Tolero Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Exelixis Inc, Genentech, Genomic Health Inc, Gilead Sciences Inc, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Sanofi Genzyme, Seattle Genetics, Taiho Oncology Inc, Takeda Oncology, and Tesaro, A GSK Company.

Research To Practice CME/CNE Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

The Westin Galleria Houston
5060 W Alabama Street
Houston, TX 77056
Hotel Phone: (713) 960-8100

Meeting Room
Woodway II and III (Fourth Level)

The Westin Galleria Houston offers both valet and overnight parking. The entrance for valet parking is on Westheimer Road. Parking rates are as follows: Overnight parking is $39 and daily valet parking is $25, plus taxes/service fees. The Westin also offers complimentary self-parking in the parking garages connected to the Galleria Mall. Please note that unfortunately, because of regulatory reporting requirements, Research To Practice is unable to validate parking.

Room Reservations
A special rate of $119 (Traditional King Room) plus applicable taxes has been arranged for meeting attendees. Please contact the Westin Galleria Houston hotel directly for reservations at (888) 236-2427.

  • A personal credit card will be required to secure accommodations.
  • Be sure to mention the following reference code when calling the hotel to receive the group rate: Year in Review 2020.
  • Room reservations must be made by Thursday, January 2, 2020. A limited number of rooms are available, and we encourage you to make your reservations early.

Thank you for your interest in our Year in Review program. At this time online preregistration is closed for this event. However, seats are still available for the program. Onsite registration will be open starting at 7:15 AM on Saturday, January 11th. If you are interested in attending, please visit our registration desk located in the foyer of Woodway II and III meeting room (Fourth Level) of the Westin Galleria Houston hotel (5060 W Alabama Street, Houston, TX 77056).

If you have any questions, please feel free to contact us via email at or call (800) 233-6153.